Synergistic activity between aztreonam and amoxicillin-clavulanate against Enterobacteriaceae-producing class B and/or class D carbapenemases with or without extended-spectrum -lactamases.

Carbapenemase-producing Enterobacteriaceae have become a major public health concern over the last decade and treatment options are limited. We evaluated the synergistic activity of the combination of aztreonam (ATM) and clavulanate for 41 -lactam-resistant clinical isolates harbouring class B or/and class D carbapenemases combined or not with extended-spectrum -lactamases (ESBLs). The MICs of ATM, with and without amoxicillin-clavulanate (AMC), were determined.

Performance evaluation of the βLACTA™ Test for rapid detection of ceftazidime resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

The chromogenic βLACTA™ test was evaluated to detect ceftazidime resistance in P. aeruginosa isolates from patients with cystic fibrosis. Best results were obtained after one hour of incubation with low sensitivity (64.

In vitro activity of tedizolid and comparator agents against Gram-positive pathogens responsible for bone and joint infections.

Tedizolid, a second-generation oxazolidinone that displays a potent activity against Gram-positive pathogens, could be an interesting option for the treatment of bone and joint infections (BJIs). The aim of the study was to determine minimal inhibitory concentration (MIC) of tedizolid against a collection of 359 clinical isolates involved in clinically-documented BJIs and to compare them to those of comparator agents used in Gram-positive infections. Of the 104 Staphylococcusaureus and 102 coagulase-negative staphylococci (CoNS) isolates, 99 and 92 % were categorized as susceptible to tedizolid, respectively (MIC25=0.